Andrew Flintoff backs campaign to increase helipads at hospitals
In December 2022, Flintoff sustained severe injuries while filming at the Dunsfold Aerodrome in Surrey for an episode of BBC show Top Gear.
The former international cricketer was airlifted to St George's Hospital in Tooting – a major trauma centre.
The helipad at the hospital was funded by a campaign with the Helicopter Emergency Landing Pads (Help) Appeal.
As he backed the campaign, Flintoff said: 'When I was airlifted, that helipad wasn't just a safe spot to land on the hospital roof, it was a vital step in giving me a second chance as I had immediate access to the specialist care which helped saved my life.
'As every cricket pitch has a wicket, every hospital that needs one should have a helipad.'
The Help Appeal said that there have been 30,000 landings on the 32 NHS hospital helipads funded by the charity across the country.
It has also funded 23 major upgrades at other hospital helipads.
The charity is aiming to fund 40 new and upgraded helipads.
Robert Bertram, chief executive of the Help Appeal, said: 'We are incredibly grateful to have Freddie's support, especially knowing that his life was saved thanks, in part, to a Help Appeal-funded helipad. His story highlights exactly why the charity's work is so vital – seconds count in a medical emergency and that helipad made all the difference.
'Freddie's backing brings invaluable awareness to the importance of rapid access to emergency care for everyone, everywhere.'
Sir Keith Porter, emeritus professor of clinical traumatology at the University of Birmingham, said the charity plays a 'crucial part' in getting patients to the right hospital at the right time.
He added: 'Helicopter Emergency Medical Services have the ability to deliver critical care teams at or close to the side of a patient and then to transport them to the most appropriate hospital for their clinical needs, in the case of injury, usually a major trauma centre.
'Minutes count, particularly for patients with life-threatening bleeding, where the extra journey time can make the difference between life and death.
'The Help Appeal, by funding on-site helipads, helps facilitate the prompt delivery of patients directly into the emergency department with a trolley-push from the landing site.'
Flintoff also recently visited the NHS staff who cared for him after the accident at St George's Hospital.
He praised health workers in the NHS as 'superheroes' and described the aftermath of the crash as the 'the lowest I've ever been'.
The 47-year-old praised the 'expertise, love and compassion' shown by staff at the hospital during his time of need.
During a documentary about the accident, Flintoff described how he used the split-second decision-making from his cricketing days to try to reduce the impact of the crash.
He said he was 'pulled face-down on the runway' for about 50 metres under the car.
The former England star said he thought he had died in the accident.
For months after the crash, Flintoff disappeared from public view and would leave his house only for medical appointments
His recovery has been documented in a documentary, Flintoff, streamed on Disney+.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Nyxoah Reports Second Quarter Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Second Quarter Financial and Operating ResultsFDA Approves Genio® System for U.S. Market; Company Begins Commercial Launch Mont-Saint-Guibert, Belgium – August 18, 2025, 10:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ('Nyxoah' or the 'Company'), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today reported financial and operating results for the second quarter of 2025. Recent Financial and Operating Highlights Received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the Genio system, the first and only bilateral hypoglossal neurostimulation therapy approved in the U.S. Kicked off the U.S. commercial launch of the Genio system DREAM pivotal study data published in the Journal of Clinical Sleep Medicine Revenue for the second quarter of 2025 was €1.3 million, compared to €0.8 million in the second quarter of 2024, representing 74% year over year growth Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, compared to €63.0 million at the end of March 31, 2025. "This FDA approval represents a historic milestone for Nyxoah and marks the beginning of what we expect to be a transformational period for our company," commented Olivier Taelman, Nyxoah's Chief Executive Officer. "Genio is now the first and only bilateral hypoglossal neurostimulation therapy approved in the United States, offering a truly differentiated solution for OSA patients who have been underserved by existing therapies. Our world-class commercial team is in place, and we have begun to execute on our commercial strategy.' FDA PMA Approval As previously disclosed, on August 8, 2025, the Company received FDA PMA for its Genio system, marking a historic milestone for Nyxoah. Genio's unique design utilizes bilateral stimulation, and offers patients a leadless, full-body 1.5T and 3T MRI compatible, non-implanted battery solution, powered and controlled by a wearable component. The Genio system's FDA approval was supported by the high-quality, differentiated safety and efficacy data from the Company's DREAM pivotal trial, which demonstrated that Genio is efficacious regardless of a patient's sleeping position. This is a critical differentiator as on average, people sleep in a supine position between 35% and 40% of the night. The DREAM study measured position-specific outcomes and demonstrated a 66.6% median AHI reduction while patients slept in a supine position despite the fact that the number of airway obstructions can double in this position. This reduction compares favorably to the 71.0% reduction in AHI shown while patients slept in a non-supine position. CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS (unaudited)(in thousands) For the three months ended June 30 For the six months ended June 30 2025 2024 2025 2024 Revenue 1 340 771 2 404 1 992 Cost of goods sold ( 490) ( 281) ( 896) ( 735) Gross profit € 850 € 490 € 1 508 € 1 257 Research and Development Expense (10 059) (7 472) (19 048) (14 671) Selling, General and Administrative Expense (10 672) (6 383) (23 063) (12 355) Other income 31 58 115 249 Operating loss for the period € (19 850) € (13 307) € (40 488) € (25520) Financial income 2 858 2 069 5 480 3 477 Financial expense (3 337) (1 445) (7 579) (2 436) Loss for the period before taxes € (20 329) € (12 683) € (42 587) € (24479) Income taxes ( 278) ( 441) ( 404) ( 551) Loss for the period € (20 607) € (13 124) € (42 991) € (25030) Loss attributable to equity holders € (20 607) € (13 124) € (42 991) € (25030) Other comprehensive loss Items that may be subsequently reclassified to profit or loss (net of tax) Currency translation differences 232 ( 82) 230 ( 22) Total comprehensive loss for the year, net of tax € (20 375) € (13 206) € (42 761) € (25052) Loss attributable to equity holders € (20 375) € (13 206) € (42 761) € (25052) Basic Loss Per Share (in EUR) € (0.551) € (0.428) € (1.149) € (0.843) Diluted Loss Per Share (in EUR) € (0.551) € (0.428) € (1.149) € (0.843) CONSOLIDATED STATEMENT OF FINANCIAL POSITION (unaudited) (in thousands) As at June 302025 December 31 2024 ASSETS Non-current assets Property, plant and equipment 5 015 4 753 Intangible assets 51 407 50 381 Right of use assets 3 059 3 496 Deferred tax asset 76 76 Other long-term receivables 1 799 1 617 € 61 356 € 60 323 Current assets Inventory 5 332 4 716 Trade receivables 1 330 3 382 Contract assets 1 508 − Other receivables 3 014 2 774 Other current assets 944 1 656 Financial assets 20 257 51 369 Cash and cash equivalents 22 729 34 186 € 55 114 € 98 083 Total assets € 116 470 € 158 406 EQUITY AND LIABILITIES Share capital and reserves Share capital 6 431 6 430 Share premium 314 388 314 345 Share based payment reserve 11 645 9 300 Other comprehensive income 1 144 914 Retained loss (260 211) (217 735) Total equity attributable to shareholders € 73 397 € 113 254 LIABILITIES Non-current liabilities Financial debt 18 928 18 725 Lease liability 2 157 2 562 Provisions 404 1 000 Deferred tax liability 34 19 Contract liability 225 472 Other liability 379 845 € 22 127 € 23 623 Current liabilities Financial debt 246 248 Lease liability 1 071 1 118 Trade payables 9 408 9 505 Current tax liability 3 990 4 317 Contract liability 460 117 Other liability 5 771 6 224 € 20 946 € 21 529 Total liabilities € 43 073 € 45 152 Total equity and liabilities € 116 470 € 158 406 RevenueRevenue was €1.3 million for the second quarter ending June 30, 2025, compared to €0.8 million for the second quarter ending June 30, 2024, representing a 74% year over year increase. Cost of Goods SoldCost of goods sold was €490,000 for the second quarter ending June 30, 2025, representing a gross profit of €0.9 million, or gross margin of 63.4%. This compares to cost of goods sold of €281,000 in the second quarter ending June 30, 2024, for a gross profit of €0.5 million, or gross margin of 63.6%. Research and DevelopmentFor the second quarter ending June 30, 2025, research and development ('R&D') expenses were €10.0 million, versus €7.5 million for the second quarter ending June 30, 2024. The increase in research and development expenses was primarily due to higher R&D activities offset by a decrease in clinical study expenses. Selling, General and AdministrativeFor the second quarter ending June 30, 2025, selling, general and administrative expenses were €10.7 million, versus €6.4 million for the second quarter ending June 30, 2024. The increase in selling, general and administrative expenses was primarily due to an increase in costs to support the commercialization of Genio system, including the Company's overall scale-up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval. Operating LossTotal operating loss for the second quarter ending June 30, 2025 was €19.9 million, versus €13.3 million in the second quarter 2024, respectively. This was driven by an increase in selling, general and administrative expenses to support commercialization of the Genio system, including the Company's overall scale-up preparations for the commercialization of Genio system in the US in connection with the receipt of FDA approval, and increased R&D activities offset by a decrease in clinical study expenses. Cash PositionAs of June 30, 2025, cash, cash equivalents and financial assets totaled €43.0 million, compared to €63.0 million at the end of March 31, 2025. The Company also has a term debt facility with €27.5 million of remaining availability which can be drawn down in two equal tranches subject to revenue and other financial milestones. Second Quarter 2025Nyxoah's financial report for the second quarter of 2025, including details of the consolidated results, are available on the investor page of Nyxoah's website ( Conference call and webcast presentation Company management will host a conference call to discuss financial results on Monday, August 18, 2025, beginning at 10:30pm CET / 4:30pm ET. A webcast of the call will be accessible via the Investor Relations page of the Nyxoah website or through this link: Nyxoah's Q2 2025 Earnings Call Webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following link: Events | Nyxoah Investors required to join the live call. To ensure you are connected prior to the beginning of the call, the Company suggests registering a minimum of 10 minutes before the start of the call. The archived webcast will be available for replay shortly after the close of the call. About Nyxoah Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah's lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors' therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65. For more information, please visit Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device. Forward-looking statements Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio system; the potential advantages of the Genio system; Nyxoah's goals with respect to the potential use of the Genio system; the Company's commercialization strategy and entrance to the U.S. market; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the 'Risk Factors' section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 20, 2025 and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward- looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Contacts: NyxoahJohn Landry, CFOIR@ For MediaIn United StatesFINN Partners – Glenn For MediaBelgium/FranceBackstage Communication – Gunther De Backergunther@ International/GermanyMC Services – Anne Henneckenyxoah@ Attachment ENGLISH_Q2 2025 Earnings PR_FINAL
Yahoo
3 hours ago
- Yahoo
The six things that make your anxiety worse (and what to do instead)
What people don't realise about anxiety disorders, says Prof Oliver Robinson of University College, London, is just how commonplace they are. One in four of us experience a clinically significant level of anxiety at some point in our lives, and at any given time, 'around 20 to 25 per cent of the population report being extremely worried,' Prof Robinson says. As a mental health condition, anxiety is also unique in that 'we all know what it feels like,' says Prof Robinson. While there's a big difference between feeling down at times and being depressed, anxiety is the body's healthy response to danger or threats. People with anxiety disorders find that those feelings fire at the wrong time, because of things that don't pose danger at all – social situations, big deadlines, or even a spider in the corner of the room. Most of us know how that feels, but when it happens consistently, it can get in the way of work, socialising, family time, and a generally healthy life. There are very effective treatments for anxiety, such as medication (through SSRI drugs, also used to treat depression) as well as exposure therapy and cognitive behavioural therapy. Three quarters to two thirds of patients find one of these, or a mix, highly effective in treating their symptoms, Prof Robinson says. The rest may have to manage their symptoms in the long run. Prof Robinson is clear that 'there is no substitute for anxiety treatment' but many people find that anxiety is easier to manage (and bring down to a subclinical level) through some healthy lifestyle tweaks. Here are the things that may make your anxiety worse – and what to do instead. Moping alone at home Anxiety is prompted by something that is causing you fear. Many of those diagnosed with an anxiety disorder struggle with social anxiety, which can cause fear of big settings like parties, as well as one-on-one interactions in some cases. 'This leads some people to spend a lot of time alone,' Prof Robinson points out. Aside from the health-worsening effects of social isolation, this actually worsens social anxiety itself in the long run. 'When you don't have any real-life examples to rely on, your worst fears become confirmed, in a way, which makes it much harder to then face your fears and go to that party or lunch with friends,' says Prof Robinson. Time alone without stimulation can also cause rumination, obsessive patterns of negative thinking that are a huge driver of both anxiety and depression. What to do 'Try not to avoid doing the thing that's bothering you, even if it's just once in every 10 times that the fear comes up,' Prof Robinson says. 'Evidence shows that facing your fears is the best way to stop being scared of them, as you recognise and gradually re-learn that there is no real danger.' Easing yourself in gradually, for example by meeting a trusted friend for a coffee before going to an exercise class full of strangers, can be helpful, as this gradually increases your exposure to the source of your fear. This goes for any kind of anxiety. 'Avoiding the source of your fear entirely will only make things worse.' Winding down with a glass of wine Alcohol makes you relax – it's a fact as true as the sky is blue. When you have a drink, it reduces your inhibitions and prompts the release of dopamine, the feel-good chemical in your brain. These effects are short-lived, however, and relying on them to soothe anxiety can come with the ugly side-effect of knocking the brain's hormonal balance out of whack, leading to worsened anxiety the next day (otherwise known as 'hangxiety'). Alcohol also interrupts sleep and worsens sleep quality, even if having a nightcap can help you to nod off. Some research suggests that wine and prosecco may be worse for anxiety than some other drinks. A low-sugar option like a hard seltzer may prove to be easier to tolerate. 'Alcohol can help people in social situations, if it's used in a controlled way,' says Prof Robinson – 'only you can know if it's really helping or causing more problems than it is helping with'. What to do Try a different way to wind down in the evenings. Research suggests that a nighttime drink can be calming in its ritual and 'treat' feeling as much as in its actual psychoactive effects. Having a hot (caffeine-free) drink can be just as soothing and will not disrupt your sleep. This makes it easier to enjoy the odd drink in a social setting without feeling a knock-on effect on your anxiety. Setting your alarm too early Sleep is the bedrock of good health, and a lack of it worsens stress like nothing else. No wonder, then, that even healthy adults who are underslept report feeling more anxious and low in the daytime. Anxiety can both cause and be worsened by poor sleep. 'They're certainly hard to tease apart, as being anxious can leave you tossing and turning,' Prof Robinson points out. In the long term, sleep deprivation impairs the function of the parts of your brain that regulate emotion, while upping activity in the amygdala, the part of your brain in charge of your fear response. An inability to sleep is anxiety-provoking in itself. What to do Give yourself the opportunity to get enough sleep, says Prof Robinson. Ideally this is by going to bed at least eight hours before your alarm is set to go off in the morning. If you're used to tossing and turning, going to bed early might be the last thing you want to do, 'but if you're up for 20 hours a day then there's no chance that you can get the rest you need'. There are tried and tested tricks to quiet racing thoughts before bed, such as box breathing, and building a bedtime routine can help you drift off to sleep more easily too. It can also be helpful to distance yourself from the causes of your anxiety before bed. If you're anxious about work, don't check your emails while you're tucked in, or else 'your behaviour might prompt worrying thoughts that wouldn't have come up otherwise,' Prof Robinson says. Drinking too much caffeine On that note, you might well be in the habit of topping up your poor sleep with copious amounts of tea or coffee. This might help keep you alert, but that's because caffeine is a stimulant, and it prompts the release of cortisol, the 'fight-or-flight' hormone. It causes your body as well as your brain to 'wake up', which is why it gives some people jitters and heart palpitations as well as more energy. The problem here is that 'the relationship between your body and your mind works in both directions when it comes to anxiety,' says Prof Robinson. Though even scientists 'don't fully understand the link', caffeine is known to prompt or worsen symptoms of anxiety, and a number of studies suggest that caffeine consumption can have a detrimental impact on anxiety and also increase the risk of its incidence in the long term. Fizzy drinks may contain sugar or sweeteners as well as all the caffeine in a standard cup of coffee or more, wreaking further havoc on your sleep. What to do Avoid drinking coffee on an empty stomach. Eating something before you have your first mug of the day can slow the body's absorption of caffeine, and release of cortisol with it, reducing the chance that you will feel it enough to worsen your anxiety in the first place. Cutting out coffee 'isn't one of those panaceas where it will fix your anxiety with no other work,' says Prof Robinson, but if you suffer from anxiety then it is important to experiment with the amount of coffee you drink 'to find out what works for you'. Fizzy drinks are best replaced with healthy and caffeine-free alternatives like flavoured sparkling waters, or herbal tea. Treating yourself with sugary food to boost your mood Yet it's easy to rely on sweet treats or a packet of crisps to quell anxiety. The endorphins released when you eat something you enjoy can balance out the anxiety in your brain and body, soothing your nervous feelings. This can lead to emotional overeating or, in the worst cases, food addiction. Much of the advice given for managing anxiety 'is the advice people are given to live a healthy life in general,' says Prof Robinson. Like sleeping well, eating well is a core part of that. Plenty of studies show that a diet high in ultra-processed food is linked to increased risk of, and in fact worsened, anxiety. A healthier diet meanwhile is linked to improved symptoms of anxiety and a reduced risk of experiencing it overall. What to do Try to stick to a Mediterranean diet. 'There isn't much good evidence for whether specific foods can improve or worsen anxiety,' Prof Robinson says, but we do know that the Mediterranean diet – which is based on whole foods, with lots of healthy fats, nuts and lean proteins – supports overall health as well as brain and hormonal health in the long as with alcohol, cutting out the foods you rely on to give yourself a mood boost may not prove helpful in the long run. It's all about keeping them to an occasional treat, Prof Robinson says. Not moving enough A number of studies have linked sedentary lifestyles to increased risk of anxiety. Intentional exercise, meanwhile, releases feel-good hormones and can reduce stress. Adults who engage in regular exercise experience fewer symptoms of depression and anxiety, other research has found. Exercise triggers the release of endorphins, which have mood-boosting effects, while also regulating the body's stress response system. What to do instead Try to get in the 150 minutes of cardiovascular exercise recommended each week by the NHS. That could mean walking, jogging, swimming or taking part in an aerobics class. 'We don't know exactly why exercise works to help with anxiety in the long term, but it may have something to do with reducing inflammation,' says Prof Robinson. The SSRI drugs prescribed for anxiety also reduce inflammation, he points out. Other forms of exercise like yoga, which are more meditative, have been linked to reduced levels of anxiety when practised regularly, and may also be worth trying. 'The practical accomplishment of picking up something new may also boost your confidence and improve your self-esteem, which can be important in the process of overcoming anxiety,' says Prof Robinson. FAQs Does anxiety worsen with age? 'Normal anxiety is pretty consistent, but clinical anxiety disorders tend to be low in childhood, reach a peak in adulthood and then decline in old age,' says Prof Robinson. Some research suggests that older adults are better at regulating their emotions. This can be attributed to a variety of factors, such as fewer stressors and different life perspectives. Can anxiety ever go away? Sometimes 'anxiety will go away on its own,' or reduce to a subclincial level over time, says Prof Robinson. However, it is always best to seek treatment if you believe that you may have an anxiety disorder. 'Around two thirds to three quarters of people with an anxiety disorder are able to make a recovery that means they no longer reach a clinical threshold,' he says. Why does anxiety get worse at night? 'Not everyone's anxiety gets worse at night, but there are a number of possible reasons it might,' says Prof Robinson. 'You may have learnt to associate night-time or darkness with threats,' he says, and 'there are also less distractions, so when you are lying in bed you start ruminating and worrying about bad things that might happen. You may also start to worry about not getting enough sleep which compounds the other problems, leading to a negative spiral.' How to manage anxiety From Professor Robinson Ultimately, everyone's anxiety is different, and there is no one-size-fits-all way to approach it. If it is getting in the way of you living your life, the best thing you can do is contact your GP who can get you into suitable treatments. The solutions depend on the problem – if you are avoiding things that aren't actually that harmful, like social situations, then setting yourself the task of being brave and going to more social situations can help. If you are lying in bed worrying about the state of the world because you read your phone just before bed, you can set yourself a target of not looking at your phone last thing at night before bed. These are opposite actions – approaching social situations or avoiding negative information before bed – and if you get them the wrong way around, by avoiding social situations and looking at your phone right before bed, you may make your symptoms worse. This is why it is often helpful to get professional help. Anxiety is very common and psychologists are very used to tailoring treatments to your specific circumstances. You may also benefit from medication, but this is only available on prescription and so you will have to see your GP to get it. Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.


Bloomberg
3 hours ago
- Bloomberg
Geopolitics in Spotlight Ahead of Retail Earnings, Jackson Hole
Get a jump start on the US trading day with Matt Miller and Katie Greifeld on "Bloomberg Open Interest." Ukrainian President Volodymyr Zelenskiy and his European allies meet President Trump in Washington today. Retail earnings this week will shed light on the health of US consumers. Novo Nordisk is slashing the cost of Ozempic for cash-paying patients to $499 a month and partnering with GoodRx to offer it at the same price at US pharmacies. GoodRx CEO talks to Open Interest about offering the best prices on drugs to consumers. (Source: Bloomberg)